REKAMBYS

This brand name is authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Israel, Italy, Japan, Lithuania, Poland, UK.

Active ingredients

The drug REKAMBYS contains one active pharmaceutical ingredient (API):

1	Rilpivirine UNII FI96A8X663 - RILPIVIRINE
	Rilpivirine is a diarylpyrimidine NNRTI of HIV-1. Rilpivirine activity is mediated by non-competitive inhibition of HIV-1 reverse transcriptase (RT). Rilpivirine does not inhibit the human cellular DNA polymerases α, β and γ.
	Read more about Rilpivirine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
REKAMBYS Prolonged-release suspension for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J05AG05	Rilpivirine	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AG Non-nucleoside reverse transcriptase inhibitors
Discover more medicines within J05AG05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1835535, 1835546
FI	Lääkealan turvallisuus- ja kehittämiskeskus	093653
FR	Base de données publique des médicaments	60150638
IL	מִשְׂרַד הַבְּרִיאוּת	9040
IT	Agenzia del Farmaco	049280011, 049280023
JP	医薬品医療機器総合機構	6250409A1022, 6250409A2029
LT	Valstybinė vaistų kontrolės tarnyba	1091686, 1091687
PL	Rejestru Produktów Leczniczych	100445800, 100445816